Report Overview

The UK Hunter Syndrome Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Hunter syndrome, also known as mucopolysaccharidosis type II (MPS II), is a rare genetic disorder caused by an iduronate-2-sulfatase enzyme deficiency. MPS II is a rare lysosomal inborn error of metabolism that affects every organ of the body. In some people, the brain may be affected in combination with physical symptoms, such as hearing problems, bone, and joint malformation, and heart and breathing difficulties. Their bodies can't break down a kind of sugar that builds bones, skin, tendons, and other tissue.

The MPS II is an X-linked genetic condition that mostly affects males than females. Although the age of onset, disease severity, and the rate of progression of the disease varies significantly, initial symptoms and findings associated with MPS II usually become apparent in children from two to four years of age. A study in the UK indicated an incidence among males around one in 130,000 male live births. The Hunter syndrome belongs to a larger group of about 50 inherited disorders collectively known as lysosomal storage disorders.



Market Growth Drivers

The introduction of novel therapies, robust product pipeline, rising government initiatives for creating awareness regarding the Hunter syndrome diagnosis and its treatment, and its available therapeutic options are expected to significantly fuel the market growth over the forecast period.

An increase in the number of patients suffering from mucopolysaccharidosis II is likely to fuel the market growth during the forecast period. In addition, rise in healthcare expenses and government initiatives for the betterment of health. Increased R&D activities to counter Hunter syndrome in children are more likely to propel the market demand during the forecast period.

Market Restraints

Increasing collaboration and technological advancements are projected to bring new growth avenues for market players during the forecast period. While the high cost of approved therapeutics and lower treatment rates hampers the market.